



FIG. 1.

2/17









FIG. 4.



STOP

FIG. 5.




FIG. 6.

Sand Sind Hall that the fact that

U

æ

j.

MEDICAL PATIENTS Inventor(s): Richard Burgess

Atty Dkt No.: 34702/214150




FIG. 7.

$\label{title: SYSTEM} \textbf{METHOD AND COMPUTER PROGRAM PRODUCT FOR IMPROVING TREATMENT OF } \\$

MEDICAL PATIENTS Inventor(s): Richard Burgess Atty Dkt No.: 34702/214150




FIG. 8.

8/17




FIG. 9.

9/17 122 -File Edit View Favorites Tools Help 4-Back v → v @] (1) Search Travortes Weda J 3 v 3 13 v 13 11 its Private MANNE OUSATOday Welcome to TIME.com ▼ PG0 Address 🕏 I Funda a " " date of [tage aget Agend Gend in o - 130 Supplied to ***** C 1** 142 ions Medications 143 134 136 138 140 126 tinitti fishasoo Privred phome RT Gona - Trobusts - 102 102

FIG. 10.

10/17




FIG. 11.

11/17




FIG. 12.




FIG. 13.

			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		, , ,
File Edit View Favor	tes Tools Help			4 17 5 3 C A	
4-Back 3	∭ Search	Favorites Med	to 3 中 3	. Unks @Finance @CNN	MSN8C @USAToday @Welcome to
Address (6)					
142 00 147 1					
		. **		Can Day Down	anim Transmit
HIVic Do	main E	kpert Re	quest Qu	ieue for Dr. Don	nam expert
PNew Physician Pr				st Date	
Name of Requesti	ng Physician		29-Oc		1
Dr Ima Neww Dr Ben Beforee			30-Oc		İ
Dr Ben Beloree					
					<i>–</i> 166
					<u>/- 100</u>
r New Consult Req	mests for Dr. De	man Expert -			
Requesting Physi	cian Request l	Date Days Since		ecimen No. / Collection Date	Type of Request
Dr William Tell	29-Oct-2	001 2	300	OCCOCYCOCYCK 18-Dec-2001	Impai Treatment
Dr Rossini	30-Oct-2	001 1		CXXXXXXXXX 18-Der-2001	Imual Treatment
Dr Smith	30-Oct-2	001 1		CXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	Virologic Failure
Dr Havacold	30-Oct-2	001 1		CXXXXXXXXXXXX 17 Dec-2001	Virologic Failure
Dr Jones	30-Oct-2	001 1	200	OOOOOOOOXX 17-Dec-2001	Toxacity Problem
Dr Brown	31-Oct-2) <u>XX</u>	CXXXXXXXXX 17-Dec 2001	Virologic Fadure
Dr Red	31-Oct-2		300	OCCOCCCCC 17-Dec 2001	Toxicity Problem
Dr Black	31-Oct-2		300	0000000000 17-Dec-2001	Instal Treatment
Dr Green	31-Oct-2	001 0) XXO	OXXXXXXXX 17-Dec-2001	Virologic Failure
I					
Previous Consult	: Requests for D Request	r. Domain Exper Reply Date	Days to Repl	Specimen No./ Collection	Date Type of Request
Requesting Physician	Date	TABLE TARKS	Days as Mepi		
Dr William Tell	29-Oct-2001	2		XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	-2001 Instal Treatment
Dr William Leil Dr Rossmi	30-Oct-2001	1		XXXXXXXXXXXXXXXX 16-De	
Dr Rossmi Dr Smith	30-Oct-2001	;		XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	
	30-Oct-2001	;		XXXXXXXXXXXXXX 16-De	
Dr Havacold	30-Oct-2001	;		XXXXXXXXXXXXXXX 16-De	
Dr Jones Dr Brown	31-Oct-2001	0		XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	
Dr Brown Dr Red	31-Oct-2001	ő		XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	
	31-Oct-2001	ŏ		XXXXXXXXXXXXXXXX 15-De	
Dr Black				XXXXXXXXXXXXXXXXX 14-De	

FIG. 14.

Title: SYSTEM, METHOD AND COMPUTER PROGRAM PRODUCT FOR IMPROVING TREATMENT OF MEDICAL PATIENTS
Inventor(s): Richard Burgess
Atty Dkt No.: 34702/214150

Edit View Favorites Tools Help	dia E
ew Physician F	
equesting Physician Profile	
me Dr Ima Neww cace Jersey Shores Medical	
User Since 28-Oct-2001	
fessional Background	

FIG. 15.

File Edit View Favorites	Tools Help Links Fi	nance (ACNN, EMSNBC (E) (B) Media (3) (A) (A) (A)	O Address	lund Signo, Slundon		• ∂·∞ .
W			94.	, , ,	*** *** ***	
	itment Repl					
	XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	ollection Date: dd-mmr	11-7777			
Gender: Mais Age	29 Height /2 m	Weight 16:35 BMI 22	: 6			
1	reconversion Fee 2001					
CD4 count at time of		Next most recent CD4 :	ounr 550 pa l Jur 23	001		
Most recent CD4 (on	d 8400 nm 29 5ep 2001,	Next must recent viral lo	ad 1100 on 1 Jun 20	C1		
Climical Symptoms for						1
1		m va request form relative to	clinical synutoms			
	atoms C Date of Oupe 10.					
		na on request "cris relative to	, o morbiditier			;
	ats regular meals. Patients	an on recuest form relative to	الله الله			
Patient Preferences	.,					
Comments	minut più turimustand lipiùs ca	an na request tours relative to	chantal yang to as			
	at's Ability to Adhere to		_	_		
Comments	mbot pared search byant	a, un request four relative to	paties i's audity to solve	re so therapy		^
L						1 ! ^
						1
Resistance N	/utations TI Protesse	Polymorphisms Rm Gene - Pro ease	Resistance (eta or chui	e u·s (*enotype)		
No. 39. 12	21.1			t 33~ are accordated t	wit 12120171 (* dual re	* SISTNING
94	77 V			_		
	•	102		10)2	1
11		102				
regimen include potent nucleosides and a prof	not show genotypic evident nal tomonty, patient complisa tease inhibitor."	vant the following printed of ce of significant drug resistant ance with past medical treatm milicant drug resistance. We a past medical treatments, dru	ents, drug absorption as			
f "This isolate does regimen include potent mucleosides and a proi f "This isolate shows include potential toxics a protease minister" First Regimen (chi	not show genotypic evident hal toxicity, patient complies tease inhibitor " igenotypic evidence of sign ity, patient compliance with patient compliance with reck all that apply) Nucleosides	te of significant drug resistance with past medical treatm indicant drug resistance. We a past medical treatments, drug resistance.	ents, drug absorption as recommend an initial co- ug absorption and drug i	nerse of treatment Issue metabolism. Consider a	s to consider in choosing regimen containing nucleo	
if "This solate does if regimen include potent mucleosides and a proid if "This is rolate shows include potential tootic a protease inhibitor" First Regimen (child tootic a protease inhibitor "This is related to the protease inhibitor" First Regimen (child a protease inhibitor "This is related to the protease inhibitor" First Regimen (child a protease inhibitor "This is related to the protease inhibitor")	not show genotypic evident all toxicity, patient comphastease milotice. genotypic evidence of signty, patient comphance with comphance with patient comphance with Nucleosides Nucleosides 1 d	a ganciant organization of the control of the contr	ents, drug absorption at recommend an initial co- ig absorption and drug in the second	nerse of treatment Issue metabolism. Consider a	s to consider in choosing regimen containing nucleo	
f "This isolate does a regimen include potent nucleosides and a proint of the state of the sta	not show genotypic evident all toxicity, patient comphastease milotice. genotypic evidence of signty, patient comphance with comphance with patient comphance with Nucleosides Nucleosides 1 d	agancian drug resistance with past medical treatments and treatments, drug resistance. We say past medical treatments, drug resistance and reatments and reatments and reatments.	ents, drug absorption as recommend an initial co- ig absorption and drug : Prot Indinavar	nrse of treatment Issue metabolism. Consider a	s to consider in choosing regimen containing nucleo Other "Hydroxyurea	
f "This wolate does regimen include potent mucleosides and a proi This isolate shows include potential toosa a protease inhibitor " First Regimen (chi T ddl T ddl	not show genotypic evident all toxicity, patient comphastease milotice. genotypic evidence of signty, patient comphance with comphance with patient comphance with Nucleosides Nucleosides 1 d	gameane drug resistante municipal resistante de la resistante de la part medical treatments, dru part medical treatments, druger de la part medical de la resistance de la part medical treatments, druger de la resistante de la r	ents, drug absorption at recommend an initial co- ig absorption and drug in the second	nerse of treatment Issue metabolism. Consider a	s to consider in choosing regimen containing nucleo Other I Hydrosymra I Foscarnet I F	
fr "This wolate does regimen include potential micleosides and a profuse shows include potential toxica a protease milotor" First Regimen (ch. F.ZDV C. C. C. C. C. C. C. C	not show genotypic evident all toxicity, patient comphastease milotice. genotypic evidence of signty, patient comphance with comphance with patient comphance with Nucleosides Nucleosides 1 d	gameane drug resistante municipal resistante de la resistante de la part medical treatments, dru part medical treatments, druger de la part medical de la resistance de la part medical treatments, druger de la resistante de la r	ents, drug absorption at recommend an initial co- ig absorption and drug in the second	nerse of treatment Issue metabolism. Consider a	s to consider in choosing regimen containing nucleo	
fr "This wolate does regimen include potential micleosides and a profuse shows include potential toxica a protease milotor" First Regimen (ch. F.ZDV C. C. C. C. C. C. C. C	not show genotypic evident all toxicity, patient comphastease milotice. genotypic evidence of signty, patient comphance with comphance with patient comphance with Nucleosides Nucleosides 1 d	gameane drug resistante municipal resistante de la resistante de la part medical treatments, dru part medical treatments, druger de la part medical de la resistance de la part medical treatments, druger de la resistante de la r	ents, drug absorption at recommend an initial co- ig absorption and drug in the second	nerse of treatment Issue metabolism. Consider a	s to consider in choosing regimen containing nucleo Other I Hydrosymra I Foscarnet I F	
r "This isolate does r regimen include potential micleouder and a protection of the	oot show genotypic evidence and toomby, patient complisher earse milieter genotypic evidence of sign, patient compliance with genotypic evidence of sign, patient compliance w	past medical treatments, dru past medical treatments, dru past medical treatments, dru NNRTIS T C Delavarden C ERWarenz ERWarenz Dacagary IN-varapune	recommend an unital cog absorption and drug 1 Prot Indansvr I Sapunavr I Amprenavr	urse of treatment Issue metabolism. Consider a "Lithbutors Reconsyr Nelfinavyr	s to consider in choosing: regimen containing nucleo Other Thydroxywen TFoscamet	a regimen
r "This isolate does r regimen include potenti micleouder and a prot "This violate shown include potential touci a protease inhibitor" Forst Regimen (chi Forst F	oot show genotypic evidence and toomby, patient complished reare milibetor. genotypic evidence of sign, patient compliance with genotypic evidence of sign, patient complianc	past medical treatments, dru past medical treatments, dru past medical treatments, dru NNRTIS T C Delavarden C ERWarenz ERWarenz Dacagary IN-varapune	Prof. Indeasur	ness of treatment Issue metabolism. Consider a Labibitors Raconavi Nelfanyr The State of the	s to consider in choosing in eigenen containing nucleo Other "Hydroxywen "Foscamet "Ghee "Green of the choosing in the ch	a regimen
r This isolate does regimen include potential micleouders and a protection of the pr	oot show genotypic evidence and toomsty, patient complishes eare miliotice. genotypic evidence of signy, patient compliance with compliance with genotypic evidence of signy, patient compliance of signy, patient compliance of signy, patient com	to or signature depth restautors me with past me decal treatments and can treatments, dru past medical treatments, dru past medical treatments, dru NNRTIS Delawedne Elevent Elevent Elevent Newtypine Newtypine Newtypine Newtypine Newtypine Newtypine Pastrone Elevent Newtypine NNRTIS NNRTIS Pastrone Elevent El	ents, drug absorption as recommend an untial cog gabrorption and drug to the second of	urse of treatment Issue metabolism. Consider a passe Inhibitors Reconsor Nelfinavir	s to consider in choosing regimen containing nucleo	a regimen
F This wolate does regimen include potential mucleosides and a profit of the profit	oot show genotypic evidence and toomsty, patient complex evidence of significant particular and the state of significant evidence with the significant evidence evide	E of riginal and tree of restaurance with past me deal treatments, drum and can't drug resistance. We is past medical treatments, drum and tree of the control of the contr	Prot Findmayr Find	urse of treatment Issue metabolism. Consider a passe Inhibitors Roccawi Nelfinavi T Roccawi T Roccawi T Roccawi T Roccawi T Roccawi T Roccawi T Nelfinavi T Roccawi T Nelfinavi s to consider in choosing in eigenen containing nucleo Other "Hydroxywen "Foscamet "Ghee "Green of the choosing in the ch	a regimen	
r This isolate does regimen include potential micleosides and a profit of the second regimen (children of the second regimen o	oot show genotypic evidence and toomsty, patient complex evidence of significant particular and the state of significant evidence with the significant evidence evide	to or signature depth restautors me with past me decal treatments and can treatments, dru past medical treatments, dru past medical treatments, dru NNRTIS Delawedne Elevent Elevent Elevent Newtypine Newtypine Newtypine Newtypine Newtypine Newtypine Pastrone Elevent Newtypine NNRTIS NNRTIS Pastrone Elevent El	Prot Findmayr Find	urse of treatment Issue metabolism. Consider a passe Inhibitors Roccawi Nelfinavi T Roccawi T Roccawi T Roccawi T Roccawi T Roccawi T Roccawi T Nelfinavi T Roccawi T Nelfinavi s to consider in choosing in eigenen containing nucleo Other "Hydroxywen "Foscamet "Ghee "Green of the choosing in the ch	a regimen	
r This isolate does regimen include potential micleosides and a profit of the control of the con	oot show genotypic evidence and toomsty, patient complex evidence of significant particular and the state of significant evidence with the significant evidence evide	to or signature depth restautors me with past me decal treatments and can treatments, dru past medical treatments, dru past medical treatments, dru NNRTIS Delawedne Elevent Elevent Elevent Newtypine Newtypine Newtypine Newtypine Newtypine Newtypine Pastrone Elevent Newtypine NNRTIS NNRTIS Pastrone Elevent El	Prot Findmayr Find	urse of treatment Issue metabolism. Consider a passe Inhibitors Roccawi Nelfinavi T Roccawi T Roccawi T Roccawi T Roccawi T Roccawi T Roccawi T Nelfinavi T Roccawi T Nelfinavi Sto consider in choosing regimen containing nucleo	a regimen	
r This isolate does regimen include potential micleosides and a profit of the control of the con	oot show genotypic evidence and toomsty, patient complex evidence of significant particular and the state of significant evidence with the significant evidence evide	to or signature depth restautors me with past me decal treatments and can treatments, dru past medical treatments, dru past medical treatments, dru NNRTIS Delawedne Elevent Elevent Elevent Newtypine Newtypine Newtypine Newtypine Newtypine Newtypine Pastrone Elevent Newtypine NNRTIS NNRTIS Pastrone Elevent El	Prot Findmayr Find	urse of treatment Issue metabolism. Consider a passe Inhibitors Roccawi Nelfinavi T Roccawi T Roccawi T Roccawi T Roccawi T Roccawi T Roccawi T Nelfinavi T Roccawi T Nelfinavi Sto consider in choosing regimen containing nucleo	a regimen	
r Thus wolate does a reggmen meldee potent meldee other m	oot show genotypic evidence and toomby, patient compliance with the same and toomby. Patient compliance with genotypic evidence of sign, patient compliance with genotypic evidence of sign, patient compliance with genotypic evidence with genotypic	E of signature due to the control was an experience of the control was a past medical treatments, drug resistance. We is past medical treatments, drug resistance of the control of the co	Protection of the second of th	nerse of treatment Issue metabolism. Consider a space Likubitors Recommer Nelfanave Tosse Inhibitors Reconver Nelfanave Tosse Inhibitors	Sto consider in choosing regimen containing nucleo	a regimen
r Thus wolate does a reggmen include potent mucleous and a prot Thus wolate shown which the potential toute a protease mibitor a protease mibitor delegation of the protease o	check all that apply) (check all that apply)	E of signature due to the control of	Protection of the second of th	tree of treatment I seue metabolism. Consider a same Inhibitors Recognity R	Sto consider in choosing regimen containing nucleo	a regimen
r Thus wolate does a reggmen include potent mucleosides and a protest from the control of the co	oot show genotypic evidence and toomby, patient compliance with the same and toomby. Patient compliance with genotypic evidence of sign, patient compliance with genotypic evidence of sign, patient compliance with genotypic evidence with genotypic	E of signature and the desired was an additional drug resistance. We is past medical treatments, drug resistance. The signature of the signatu	Protestant of the second of th	ness of treatment Issue metabolism. Consider a nesse Inhibitors Raconave	Sto consider in choosing regimen containing nucleo	a regimen
r Thus wolate does a reggmen meldee potent meldee other m	check all that apply) (check all that apply)	E of signature due to the control was a part medical treatments, dru part medical treatments, dru part medical treatments, dru part medical treatments, dru part medical treatments of the control part medical treatments of the control part part part part part part part part	Prot Fadmaver Fadm	tree of treatment I seue metabolism. Consider a same Inhibitors Recognity R	Uther Bydropytes	a regimen
r Thus wolate does a reggmen include potent mucleosides and a protest from the control of the co	check all that apply) (check all that apply)	E of signature and the desired was an additional drug resistance. We is past medical treatments, drug resistance. The signature of the signatu	Prot Fadmaver Fadm	tree of treatment I seue metabolism. Consider a same Inhibitors Recognity R	Sto consider in choosing regimen containing nucleo	a regimen
r Thus wolate does a reggmen meldee potent meldee other m	check all that apply) (check all that apply)	E of signature and the desired was an additional drug resistance. We is past medical treatments, drug resistance. The signature of the signatu	Prot Fadmaver Fadm	tree of treatment I seue metabolism. Consider a same Inhibitors Recognity R	Uther Bydropytes	a regimen
r Thus wolate does a reggmen melde potent melde side and a protection melde side and a protection meldes and a protection meldes and a protection of the meldes and a protection of the meldes and a protection of the meldes a protection of the meldes a protection of the meldes and	check all that apply) (check all that apply)	E of signature and the desired was an additional drug resistance. We is past medical treatments, drug resistance. The signature of the signatu	Prot Fadmaver Fadm	tree of treatment I seue metabolism. Consider a same Inhibitors Recognity R	Commercial containing nucleor regimes regi	a regimen
r Thus wolate does a reggmen meldee potent meldee other m	check all that apply) (check all that apply)	E of signature and the desired was an additional drug resistance. We is past medical treatments, drug resistance. The signature of the signatu	Prot Fadmaver Fadm	tree of treatment I seue metabolism. Consider a same Inhibitors Recognity R	Commercial containing nucleor regimes regi	a regimen
r Thus wolate does a reggmen meldee potent meldee other m	check all that apply) (check all that apply)	E of signature and the desired was an additional drug resistance. We is past medical treatments, drug resistance. The signature of the signatu	Prot Fadmaver Fadm	tree of treatment I seue metabolism. Consider a same Inhibitors Recognity R	Consider in choosing regimes containing nucleo regimes containing nucleo regimes containing nucleo regimes containing nucleo regimes r	a regimen

FIG. 16.

7341 -C-1Lx			· July Franc	e Your Ander E		TA
Address (B)						<u>*</u>
-		lvage Treatm				
Patient Profile Age		Collection Date: dd-mu Weight 163 th BMT 3				
	roconversion Frb-it		•			1
CD4 count at time of	-			wa.		
		1. Next most recent CD4				
Start Cult	Current Medicutio	rts				1
2 de sodier 12/16/200 concutation 12/18/200 5, pura est 12/12/200	10					1
1	Previous Predicent	84s				- 1
Co-Morbulation Hap.	atura i * Tirologue 6 ana	N. Campunga				- (
		can on request form, relative t	ore most discr			ł
1	atricular en a Patier]
Patenta Perference of	utray p.p. Leclanear 192 for 2011	rian or request form relative to	ADI ISSUE.			- 1
1		cia, a reque i ir ma relative to	church senter ans			l
1	n's Alabsy to Adhere t neut : V. equerus phys	o Pherapy com a request two relative is	o amenda armiyin ada	ne to thropy		- 1
L						
						1
Resistance Maranes		vn.onshisini Pesii	tare			
Mesistance Margross		ymorphism Fein fant Tracture in c	CHARGED AT REALD			
1		Muta		atori and South for dust	e a dance	1
), v			ated and Robertte dual		
e Spagerind Drug Res	omens - Check if you	02	tion, a. 535 pr actors	1(02	
e Spagerind Done Re-	gracente - ("heck if you of show genotypic evider af toxicity, patient compli	02	tion, a. 535 pr actors	1(02	ong a
Suggested Drug Res "The isolate does no regimen include potentic nucleosides and a prote	gament - Check if you at show genotypic evider at tomorry, patient compli- ase inhibitor *	02 want the following printed once of significant drug resistant sance with past medical engine	ivon, a. 535 we arrore on your reply we We recommend an ents, drug absorption a	10 mindal course of treatment and drug metaboham. Con)2 : Issues to consider in choosesder a regimen containing	· L
"The isolate does no regmen include potentic nucleosides and a prote l'Time isolate shows a include potential toxicity a protease unbono?"	gmone - Check if you to show genotypes evider al towards, patient compliance within the compliance of sign patient compliance with the compliance	02	ivon, a. 535 we arrore on your reply we We recommend an ents, drug absorption a	10 mindal course of treatment and drug metaboham. Con)2 : Issues to consider in choosesder a regimen containing	L
Suggested Drug Rey This isolate does no regimen under possess unclosides and a prote protection of the	gnaoux - Check if you to show genetypic ander il towards, patient compile are substant are substant or supernotypic and endeate of support to the substant of substant or substant o	O2 woust the following printed once of agraficant drug rentland and anner with past medical frozen galicant drug rentlands. We have been been supported to the past medical weatherests, drug printed to the past medical weatherests, drug past medical weather was a support of the past medical was a support of the past med	in your reply to We recommend an ental cog absorption and drug:	minal course of treatment and drug metabolism. Con surge of treatment. Issue, metabolism. Consider A i	D2 Issues to consider in choosaider a regimen containing a regimen containing musteoside is consider in choosaing a regimen containing musteosid	L
Nuggested Prug Rep This isolate does no regimen include potential include i	gramms - Check it you. to show genotypic ender at oneity, patient compliance with the compliance of significant compliance we genotypic evidence of significant compliance we de all that opply) furface sides Fig.	O2 want the following printed ones of agalicant drug resident granted at recommendation and the printed at recommendation of the past medical recommendation of the past medical residents, drug printed to the past medical residents and past medical residents. Printed to the past medical residents are past medical residents and past medical residents and past medical residents.	in your reply The recommend an entry of the commend and drug of the commend a	mind course of Featment and drug metabolism. Con-	D2 Issues to consider in choosing a regimen continuing is to consider in choosing a regimen containing nucleoside	L
Suggested Prog Re, F This isolate does no regimen include potentia functionates and a protes and a protesse include potential toxicity a protesse inhibitor. First Regimen (chec F ZDV dd d dd	gramms - Check it you. to show genotypic ender at oneity, patient compliance with the compliance of significant compliance we genotypic evidence of significant compliance we de all that opply) furface sides Fig.	O2 want the following practed once of significant drug resistance are noted a fraction and the product of the past medical resistance. We the past medical treatments, drug many the past medical treatments of the past	in 5 may reply To your reply We recommend an untail or g absorption and drug. Todanay Todanay Todanay Todanay	minal course of freatment and drug metabolism. Consider a successful consideration of the	D2 Issues to consider in choosing a resider a regimen containing to consider in choosing a regimen, containing nucleosid. Other Frytosymen	· L
Nuggested Prug Rep This isolate does no regimen include potential include i	gramms - Check it you. to show genotypic ender at oneity, patient compliance with the compliance of significant compliance we genotypic evidence of significant compliance we de all that opply) furface sides Fig.	O2 want the following printed ones of agalicant drug resident granted at recommendation and the printed at recommendation of the past medical recommendation of the past medical residents, drug printed to the past medical residents and past medical residents. Printed to the past medical residents are past medical residents and past medical residents and past medical residents.	in 5 may reply To your reply We recommend an untail or g absorption and drug. Todanay Todanay Todanay Todanay	minal course of freatment and drug metabolism. Consider a successful consideration of the	D2 Issues to consider in choosing a resider a regimen containing to consider in choosing a regimen, containing nucleosid. Other Frytosymen	· L
Suggested Drug Re, I "This isolate does no regimen include potentic nucleosides and a prote I" This isolate shows a include potential toxicity a protease whopen" First Regimen (chec I" ZDV I" ddd I" ddo I" ddo	gramms - Check it you. to show genotypic ender at oneity, patient compliance with the compliance of significant compliance we genotypic evidence of significant compliance we de all that opply) furface sides Fig.	O2 want the following printed ones of agalicant drug resident granted at recommendation and the printed at recommendation of the past medical recommendation of the past medical residents, drug printed to the past medical residents and past medical residents. Printed to the past medical residents are past medical residents and past medical residents and past medical residents.	in 5 may reply To your reply We recommend an untail or g absorption and drug. Todanay Todanay Todanay Todanay	minal course of freatment and drug metabolism. Consider a successful consideration of the	Equals to consider in choosing a regional continuing is to consider in choosing a regional containing motion of the conta	· L
Suggested Drug Re- F The solute does no rule order and a prote- rule order and a prote rule and a prote- rule and a prot	garants - C'het le if you, si show genetype evider als arbytoge evider als arbytoge genetypine awdence of sig patent compliants we k, all that apply). Sinche exides	O2 want the following practed once of significant drug resistance are named at treatment and the product of the part medical results of the part of the p	ins sur zejty in sur zejty ie We recommend an ents, drug absorption a recommend an intial cc g absorption and drug; "Indianae" "Securiave I Amprenave I Amprenave	unhal course of treatment and drug metabolism. Con use of treatment Issue metabolism. Connected as Connected	D2 Issues to consider in choosing a regimen containing a regimen containing as to consider in choosing a regimen containing motional and the state of the state	· L
"Nuggerand Drug Me, I" The stolate does no runcionides and a prote The stolate down s reduce accessed now a protease substor T dd dd dd dd Corrunata Second Regimen (chec	gamony - Check if you, at those gamony, caude it towns, patient compile are shadow? genotypus ewdence of agenotypus ewdence of a genotypus ew	O2 want the following printed once of agusticant drug resistance are not part of the part medical strain makes with part medical strain guideant drug resistance. We in part medical treatments, drug printed to the part medical treatments, drug printed to the part medical treatments, drug printed to the part of the pa	ins sur zejty in sur zejty ie We recommend an ents, drug absorption a recommend an intial cc g absorption and drug; "Indianae" "Securiave I Amprenave I Amprenave	mal course of treatment of drug mentabolism. Get use of irrestruct. I summerabolism Consider a metabolism. Consider a metabolism. Falconave Patenave Patenav	D2 Issues to consider in choosing a regimen containing is to consider in choosing a regimen containing moteonid Other Fotoamet Fotoamet	L
"Suggested Drug Mer I'" The solute does no regamen include potents with the solution of the so	gaments - Check if you, at those generates ended to those generates and an are substitute. It all that apply) Such as the substitute of	O2 Over the following practed one of agadeaus drug rentant makes with pear more and results are successful as the pear of the	in your reply in your reply in Your reply in We recommend an artist decay absorption a metal deag absorption and drug. From Tacknown Proc. Tacknown Tac	unhal course of transmented dang metabolism. Con urste of treatment. Issue metabolisms. Congress of treatment. Issue metabolisms. Congress of transmentabolisms. Fixtonamy. Fixtonamy.	Tanuas to consider in choosing of a regimen containing is to consider in choosing a regimen containing nucleosed. Note	L
Second Regener (c) Toly Second Regener (c) Second Regener (c) Toly Second Regener (c)	gaments - Check if you, at those generates ended to those generates and an are substitute. It all that apply) Such as the substitute of	O2 want the following practed once of agalicant drug resistance and past medical aroung past medical aroung past medical aroung past medical aroung past medical resistance. We in past medical treatments, drug past medical treatments, drug past medical treatments, drug past medical treatments, drug past medical treatments and past medical pa	in your reply in your reply is We recommend an ents, drug absorption a recommend an initial cc g absorption and drug; Tudenave Tudenave Saquinave Amprenave Saguinave Saguinave Saguinave Saguinave	mal course of treatment of drug mentabolism. Get use of irrestruct. I summerabolism Consider a metabolism. Consider a metabolism. Falconave Patenave Patenav	D2 Janua to consider in choosing a regimen containing is to consider in choosing a regimen containing motional in Goder Flydrosyster Fessamet Other Fascarint Fessamet	L
Suggested Prug Rep The solute does no regenen include potentic multicontect and a protect The solute allower of Solution and the solute of Solution and the solute of Solution and the solute of Solution and the solution of Solution and the sol	gaments - Check if you, at those generates ended to those generates and an are substitute. It all that apply) Such as the substitute of	O2 want the following practed once of agalicant drug resistance and past medical aroung past medical aroung past medical aroung past medical aroung past medical resistance. We in past medical treatments, drug past medical treatments, drug past medical treatments, drug past medical treatments, drug past medical treatments and past medical pa	in your reply in your reply is We recommend an ents, drug absorption a recommend an initial cc g absorption and drug; Tudenave Tudenave Saquinave Amprenave Saguinave Saguinave Saguinave Saguinave	mal course of treatment of drug mentabolism. Get use of irrestruct. I summerabolism Consider a metabolism. Consider a metabolism. Falconave Patenave Patenav	Januar to consider in choosing a regimen containing is to consider in choosing a regimen containing motivated in Charles and C	L
Second Regimen (c) T 2DV T dd T dd T dd	gaments - Check if you, at those generates ended to those generates and an are substitute. It all that apply) Such as the substitute of	O2 want the following practed once of agalicant drug resistance and past medical aroung past medical aroung past medical aroung past medical aroung past medical resistance. We in past medical treatments, drug past medical treatments, drug past medical treatments, drug past medical treatments, drug past medical treatments and past medical pa	in your reply in your reply is We recommend an ents, drug absorption a recommend an initial cc g absorption and drug; Tudenave Tudenave Saquinave Amprenave Saguinave Saguinave Saguinave Saguinave	mal course of treatment of drug mentabolism. Get use of irrestruct. I summerabolism Consider a metabolism. Consider a metabolism. Falconave Patenave Patenav	D2 Janua to consider in choosing a regimen containing is to consider in choosing a regimen containing motional in Goder Flydrosyster Fessamet Other Fascarint Fessamet	L
Second Regimen (che Programments) Second Regimen (che Programments) Second Regimen (che Programments) Second Regiment (che Programments)	grants - Check if you, at those grants of the control of the contr	Wast the following practed once of agusticate drug resistant and an among with past medical strains makes with past medical strain and an amount of the past medical strain and an amount of the past medical weatherest. An amount of the past medical weatherest. An amount of the past medical weatherest. An amount of the past medical strains and the past medical strains and the past medical strains. Any NYRITE NRTRITE Delawardine Delawardine Delawardine Delawardine Delawardine Past medical strains Past medical	in 5 our reply e We recommend an ents, drug absorption a drug absorption and drug. From Fordinger Sudmare Amprenave Amprenave Saquanave Camprenave Camprenave Camprenave Prof. Camprenave Prof. Camprenave Prof. Prof. Prof. Camprenave Prof. Camprenave Prof. Prof. Prof. Camprenave Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof. Prof.	unhal course of treatment and drug metabolism. Con urge of treatment Issue, metabolism. Connected as English Conne	D2 Januar to consider in choosing a regimen containing a to consider in choosing a regimen containing motional and containing	L
Second Regimen (che ZDV Ks. ZDV Ks. ZDV Zdd Comments	grants - Check if you, at those grants - Check if you, at those grants conder a consequence of a grant state of a grants and the grants are stated or grants and the grants are stated or grants and grants are stated or grants and grants are grants and grants are grants and grants are grants and grants are gr	O2 want the following practed once of agalicant drug resistance and past medical arrangements are supported by the past me deal weathered. And the past me deal weathered. And TIC Edwardne Delawardne Delawar	in your reply to We recommend an ents, drug absorption and drug. Prot Parkener of Security	minal course of treatment of drug mentabelism. Geo uras of treatment Jesus more abolism. George as Eukhlitors. F. Neifenson. F. Rainnaw.	Tanuas to consider in choosaider a regimen containing is to consider in choosaider a regimen containing a to consider in choosaid in containing nucleoted. Char	L
Second Regmen (che To	grants - Check if you, as thow generally evident conditions of the condition of the conditi	O2 O2 O2 O3 O4 O4 O5 O5 O5 O5 O5 O5 O5 O5	in your reply in your reply ie We recommend an ente, drug absorption a recommend an untial co g absorption and drug Findmany if Saquinave	unhal course of treatment and drug metabolism. Con urge of treatment Issue, metabolism. Connected as English Conne	D2 Issues to consider in chooseder a regimen continuing it to consider in choosing a regimen containing nucleosed. Other Hothers	L
Second Regimen (che ZDV Ks. ZDV Ks. ZDV Zdd Comments	grants - Check if you, at those grants - Check if you, at those grants conder a consequence of a grant state of a grants and the grants are stated or grants and the grants are stated or grants and grants are stated or grants and grants are grants and grants are grants and grants are grants and grants are gr	O2 want the following printed once of agalicant drug resistant makes with past medical around makes with past medical around printed and past medical around makes with past medical weakness. We have	in your reply to We recommend an ents, drug absorption and drug. Prot Parkener of Security	minal course of treatment of drug mentabelism. Geo uras of treatment Jesus more abolism. George as Eukhlitors. F. Neifenson. F. Rainnaw.	Tanuas to consider in choosaider a regimen containing is to consider in choosaider a regimen containing a to consider in choosaid in containing nucleoted. Char	L
Second Regener (che The Regene	grants - Check if you, at those grants - Check if you, at those grants conder a consequence of a grant state of a grants and the grants are stated or grants and the grants are stated or grants and grants are stated or grants and grants are grants and grants are grants and grants are grants and grants are gr	O2 want the following printed once of agalicant drug resistant makes with past medical around makes with past medical around printed and past medical around makes with past medical weakness. We have	in your reply to We recommend an ents, drug absorption and drug. Prot Parkener of Security	minal course of treatment of drug mentabelism. Geo uras of treatment Jesus more abolism. George as Eukhlitors. F. Neifenson. F. Rainnaw.	D2 Issues to consider in chooseder a regimen containing to consider in choosing a regimen containing molecular programment of the containing molecular programment programmen	L
Suggested Drug Re- F The solute does no regener methods potential rege	grants - Check if you, at those grants - Check if you, at those grants conder a consequence of a grant state of a grants and the grants are stated or grants and the grants are stated or grants and grants are stated or grants and grants are grants and grants are grants and grants are grants and grants are gr	O2 want the following printed once of agalicant drug resistant makes with past medical around makes with past medical around printed and past medical around makes with past medical weakness. We have	in your reply to We recommend an ents, drug absorption and drug. Prot Parkener of Security	minal course of treatment of drug mentabelism. Geo uras of treatment Jesus more abolism. George as Eukhlitors. F. Neifenson. F. Rainnaw.	Danue to consider in chooseder a regimen containing is to consider in choosing a regimen containing molecular regimen containing mol	L
Second Regener (che Table	grants - Check if you, at those grants - Check if you, at those grants conder a consequence of a grant state of a grants and the grants are stated or grants and the grants are stated or grants and grants are stated or grants and grants are grants and grants are grants and grants are grants and grants are gr	O2 want the following printed once of agalicant drug resistant makes with past medical around makes with past medical around printed and past medical around makes with past medical weakness. We have	in your reply to We recommend an ents, drug absorption and drug. Prot Parkener of Security	minal course of treatment of drug mentabelism. Geo uras of treatment Jesus more abolism. George as Eukhlitors. F. Neifenson. F. Rainnaw.	Danue to consider in chooseder a regimen containing is to consider in choosing a regimen containing molecular regimen containing mol	· L

FIG. 17.

186, EUR TOT 14	vortes Tools Help					
\$ Back + № + 🔘] A OSearch 国Favo	ntes Meda (1 1 1 2 2 1	inks (Finance	BOW BWARE BI	SAToday Welcome to TIME.com	
Address 📳					Y	rp̂Go ;
Toxicity	Problem Re	oply				<u> </u>
- North Profiles	××××××××××××××××××××××××××××××××××××××	Collection Dates dd numr				
Grader Mai-	Age " Height 72 s of Seroconversion 1 cb		6			
C'D4 court at to	na of diagnosis 579		oner 550 on I has	2001		
Most recent var	Micount 92° on 29 Sep. Micoul 6100 on . 7 Sep.	2001; Next most recent CD4 : 2001, Next most rocent vir d is	and 100 am Loran 2	·cr·		
HAARI IIIsee alexinden 12/1 Zulesinden 12/1 Zageravar 12/1	Dry – Gurrent Medica 1771e — Stop Due 1877 1 10 1400 187000	Henry be inford Severe Krab	work of mysers.			
	ory Previous Medis:	artous				
Co Morbidates	Hepublis C Diabetes (sy	pc 2, 1 spression				
20 mg	ents m, us by requesting 1/1	or reductes once a treasons no nation of	endified a co			
	ations and say surremes. P words injust by responsing pl	apen in contract pening on requestrois to abve +>	Not wrom			
Panent Preioro	nces	pareins on technes, tour celutics to				
Assusment of	Patront's Ability to Adhe	in to Thurspy				
	sertions beingen too;	hy asun on recuent, reasonable to	grantement a visuals to well	oven ~ that sho		
Patient Resist	arer in Rosp					
We Prostones Mut	tetta Gerr	I objetice Partie	ance			-
Promine Mot	1 Pr trasc E	Conc Paster Cacca	rd pa to (senetype)	and OTS-VES down	g e Histolean e	
Mars ENVI	71 T 7/1 V	Mark	rd pa to (senetype)	102	ronntarur	
233 F	711 77 77	102	rd up to (printing)	- 102		ng st
Nuggested Dr	71 T 71 V and Regiments - Check it is does not show genotype or to thou genotype or to the object t	102 you want the following printed or ordered of significant drug resistant maplance with past medical treatment.	rdug to (senetyre) one at 303 are associated as your reply we want reply we recommend at the design and the senetyre as the	n mattal course of treatment	: Issues to consider in choose	ng x
Nuggested Dr	71 T 71 V and Regiments - Check it is does not show genotype or to thou genotype or to the object t	102	rdug to (senetyre) one at 303 are associated as your reply we want reply we recommend at the design and the senetyre as the	n mattal course of treatment	: Issues to consider in choose	amon and
Number of the state of the stat	I Private II 711 711 711 100 100 100 100 1	102 you won't the following practed on the following practed on the following practed on the following practed on the following practed of the fol	n vous reply We recommend as must be commend as must accommend as usual c g absorption and drug	102 a initial course of treatment and drug metabolism. Got ourse of treatment. Issue metabolism. Gonsider a course of treatment. Issue metabolism.	Taxues to consider in choosis unider a regimen continuous s to consider in choosing a regimen containing nucleosides Other	ng x
Num SNAL 233 F Numer and Dr "The rolate regimes mulcides include protesse and from the control of the contro	71 T 71 V and Regiments - Check it is does not show genotype or to thou genotype or to the object t	102 you want the following practed or other words of the following practed or other wants of the following practed or other wants of the following practed or other words and the following practed or the following practice with past medical treatments drug with past medical treatments drug with past medical treatments drug	n vous reply n vous reply n vous reply n vous reply g We recommend an ecommend an unital c g absorption and drug [Induser [Sagurany	102 n mital course of treatment and drug metabolum. Cor ourse of treatment. Issue metabolusm. Consider A t	Issues to consider in choosing a regimen containing is to consider in choosing a regimen containing nucleosides	amon and
Num SNAL 233 F Numer and Dr The rolate nucleoseds and F The rolate nucleoseds appotents a protense unbul Fart Regume Tub Tub	I Private II 711 711 711 100 100 100 100 1	102 you want the following practed or adence of significant dure resistant mylane with past medical treatment of rignificant drug resistance. We rewrite past medical treatments drug resistance. The resistance of the	a your reply a vous reply a We recommend as commond an usual e absorption and drug Ladaner	102 nutual course of treatment and drug metabolum Course of treatment. I stude metabolum Control of treatment and	Traves to consider in choosing a regimen containing a regimen containing a regimen containing a regimen containing successives [I Hydrosyura	amen and
Num SNAT 232 F -Numer and Dr F The rolate regeme suckets and f The rolate regeme sucket protesse unbi- a protesse unbi- Fart Regeme F The ddc I ddc I ddc	If the treats 71	102 you want the following pranted or adence of significant drug resistance of which past method treatments of significant drug resistance. We rewrite past medical treatments drug resistance of the wind past medical treatments drug resistance. The wind past medical treatments drug resistance of the wind past medical treatments drug resistance. The wind past medical treatments drug resistance of the wind past medical treatments drug resistance. The wind past medical treatments drug resistance of the wind past medical treatments drug	a your reply a vous reply a We recommend as commond an usual e absorption and drug Ladaner	nuntial course of freatment and drug metabolum. Corourse of treatment. Issue metabolum Consider A. Transa Industries. F. Recensive I. Nellinour.	Tissues to consider in choosing a regimen containing a regimen containing a regimen containing audicolides Other Hydrosynura	ng a
Nugge sted Dr The trolate rucheouse and The rolate nucleouse and The rolate protesse unbul- Furt Regime I ZDV I ddd I ddd I ddc	If the treats 71	102 you want the following practed or adence of significant dure resistant mylane with past medical treatment of rignificant drug resistance. We rewrite past medical treatments drug resistance. The resistance of the	a your reply a vous reply a We recommend as commond an usual e absorption and drug Ladaner	102 nutual course of treatment and drug metabolum Course of treatment. I stude metabolum Control of treatment and	Traves to consider in choosing a regimen containing a regimen containing a regimen containing a regimen containing successives [I Hydrosyura	ng a
Num SNAT 243 F Numge sted Dr F This reclate cregimen suitude in nucleous des and F This reclate cucked proteonal a proteinse inhabit a proteinse inhabit for the steep of the	If the reach it is a second of the second of	102 you want the following granted o adence of significant drug resistance of significant drug resistance of with past medical treatments drug and treatments drug resistance. We rewith past medical treatments drug resistance. To several past medical treatments. To several past medical treatments. To several past medical past me	n vous reply n	numbal course of freatment and drug metabolism. Con ourse of treatment. Issue metabolism Consider a linear Inhabitors. [Riconave Nollinove 1 Nollinove	Ensues to consider in choosing and a regimen containing a regimen containing a regimen containing successive for the containin	and and
Num SNAT 233 F Num gested Dr The relate mathematical a protesse unbule protesse unbule Fart Regens Fart Regens Todo Comments Second Regens F 2DV ddi ddi ddi	If treate II 717 717 717 717 717 717 717	102 you want the following printed o notence of significant drug resistance of significant drug resistance of with past medical treatments drug and treatments drug resistance. We rewith past medical treatments drug resistance of significant drug resistance drug resistance. We rewith past medical treatments drug resistance. To believe due to the past medical treatments drug resistance. To believe due to the past medical treatments drug resistance. To believe due to the past medical treatments drug resistance. To believe due to the past medical treatments drug resistance and the past medical treatments drug resistance. The past medical treatments drug resistance and treatments drug res	A YOUR FEED AND A CHENTER FEED AND A CHENTE	102 nutual course of treatment and drug metabolam Course of treatment. I stuce metabolam Consider A 1 Tenana Tablicana (Issues to consider in choosing a regimen containing a regimen containing a regimen containing auclosides Document	and and
Num SNAL 233 F Numge sted Dr The trolate relations and relations and relations and relations and protesse unbel First Regime The state of the s	102 you want the following practed of adence of significant drug resistance of significant drug resistance of which past method treatments drug the same of significant drug resistance. We rewrite past method treatments drug the same of significant drug resistance of significant drug resistance. We rewrite past method to same past method to sam	n vous reply n vous reply n vous reply n vous reply of the recommend as usual c absorption and drug [Industry	102 nuntial course of treatment and drug metabolism Course of treatment. I student metabolism Consider a live of treatment in the consider a live of the consider a live of the consider a live of the consideration of th	Issues to consider in choosing a regimen containing a to consider in choosing a regimen containing nucleosides Other	amen and	
Num SNALT 233 F Nugge sted Dr F The trobate regemes melicia in microaster and in microaster and a professe urbab Paret Regeme F 2DV I ddl Comments Second Rege T 2DV I ddl I ddl I ddl I ddl I ddl	If treate II 717 717 717 717 717 717 717	102 you want the following printed o adence of significant drug resistance may be a with past medical treatments drug for a with past medical treatments of a with past medical treatments for a with past medical treatments for a with past medical treatment for a with pa	A YOUR FEED AND A CHENTER FEED AND A CHENTE	102 nuntial course of treatment and drug metabolism Course of treatment. I student metabolism Consider a live of treatment in the consider a live of the consider a live of the consider a live of the consideration of th	Traums to consider in choosing a regimen containing a regimen containing a regimen containing and consider in Choosing a regimen containing nucleosides Other	amen and
Num SNAT 233 F Num ge send Dr This relate regimen meliude principal in micro meliude principal in micro meliude principal in micro meliude protential a protentia del protential a protential a protential in micro meliude protential a protential in micro meliude protential a protential in micro meliude in micr	If treate II 717 717 717 717 717 717 717	102 you want the following printed o adence of significant drug resistance may be a with past medical treatments drug for a with past medical treatments of a with past medical treatments for a with past medical treatments of a with past medical treatment for a with pas	A YOUR FEED AND A CHENTER FEED AND A CHENTE	102 nuntial course of treatment and drug metabolism Course of treatment. I student metabolism Consider a live of treatment in the consider a live of the consider a live of the consider a live of the consideration of th	Issues to consider in choosing a regimen containing a regimen containing as to consider in choosing a regimen containing nucleosides Other	ng a
Num SNAT 232 F Numge sted Dr The rolate The rolate nucleoseds and F The voltae nucleoseds and protesse unbob Fart Regime Frat Regime F	The state of the s	102 you want the following printed o adence of significant drug resistant mappianes with past method they are settlement of right and the settlement of right and they are settlement of right and r	n vous reply n vous reply n Ver recommend as ecommend as usual c g absorption and drug (Indinaver I Saquenaver I Amprenaver T Amprenaver	102 numbal course of freatment and drug metabolum Corourse of treatment. I student metabolum Consider a transport of the state Tubulanteer. [Reconsider [Nollinavar]	Ensues to consider in choosing are regimen containing a regimen containing a regimen containing auctorides Other I Hydrosyurea I Foscarnet I Syrosyurea I Foscarnet I Syrosyurea I Foscarnet	and amen
Num SNAT 233 F Nugge sted Dr F The relate The relate nucleosdes and F The solate unclude potential a protesse unbub Fart Regume 7 2DV 1 ddi Gdo F ddo F ddo F ddo F 2DV 1 ddi I ddo F 200 Second Reg F 2DV 1 ddi I ddo F 200 Comments	men (check all that apply) Nucleorides The data The d	102 you want the following granted or adence of significant drug resistance of significant drug resistance of which past medical treatments of the same of significant drug resistance. We rewith past medical treatments drug resistance. The same of significant drug resistance of significant drug resistance. The same of significant drug resistance of significant drug resistance. The same of significant drug resistance of significant drug resistance. The same of significant drug resistance of s	A your reply The very recommend as a second an annual case of the commend as a second an annual case of the case	102 a mind course of treatment and drug metabolism Course of treatment. I stuc metabolism Consider a metabolism Consideration of the metabolism of the meta	Tissues to consider in choosing a regimen containing a regimen containing as to consider in choosing a regimen containing auclosides Other	amen and
Num SNAT 272 F Nugge sted Dr The trolate nucleonder and Formalize proteste tribb First Regime First Regime Formalize Germanute Second Regime First DV I ddl Gde Comments Comments Comments Comments Therd Regime	The trans II 71T 71T 71T 71T 71T 71T 71T 7	102 102 you want the following granted a address of significant drug resistant mappianes with past method they are settlement of right for the settlement of the settlement	A YOUR FORM TO LETTENERS TO THE STATE OF THE	nutual course of treatment and drug metabolism Course of treatment. I student metabolism Consider A. Teneral Tabulators [Tisues to consider in choosing a regimen containing a regimen containing a regimen containing auctionates to consider in choosing a regimen containing nucleotides Other	amen and
Num SMAT 274 F Num ye send Dr The robate The robate nucleosder and F The yolate nucleosder and F The yolate protesse unbub Farst Regume From Regum	men (check all that apply) Nucleorides The data The d	102 you want the following practed or adence of signaficant drawing practed or adence of signaficant drawing practice of signaficant drawing practice of signaficant drawing part medical treatment of rignaficant drug resistance. We rewrite part medical treatment of rignaficant drug resistance. We rewrite part medical treatment of rignaficant drug resistance. We rewrite part medical treatment of rignaficant drug resistance. The resistance of resis	A your reply The very recommend as a second an annual case of the commend as a second an annual case of the case	102 a mind course of treatment and drug metabolism Course of treatment. I stuc metabolism Consider a metabolism Consideration of the metabolism of the meta	Cher Foscarnet	
Num SNAT 233 F Nugge sand Dr The rolate The rolate nucleoseds and F The rolate nucleoseds and F The rolate nucleosed personal a protesse unbob Fart Regume Frat Regume Fra	men (check all that apply) Nucleorides The data The d	102 you want the following practed or adence of signaficant drawing practed or adence of signaficant drawing practice of signaficant drawing practice of signaficant drawing part medical treatment of rignaficant drug resistance. We rewrite part medical treatment of rignaficant drug resistance. We rewrite part medical treatment of rignaficant drug resistance. We rewrite part medical treatment of rignaficant drug resistance. The resistance of resis	A your reply The very recommend as a second an annual case of the commend as a second an annual case of the case	102 a mind course of treatment and drug metabolism Course of treatment. I stuc metabolism Consider a metabolism Consideration of the metabolism of the meta	Titues to consider in choosing a regimen containing a regimen containing a regimen containing auctionates to consider in choosing a regimen containing nucleosides	
Num SNAT 233 F Nugge sand Dr The rolate The rolate nucleoseds and F The rolate nucleoseds and F The rolate nucleosed personal a protesse unbob Fart Regume Frat Regume Fra	The trans II 711 717 717 717 717 717 717	102 you want the following practed or adence of signaficant drawing practed or adence of signaficant drawing practice of signaficant drawing practice of signaficant drawing part medical treatment of rignaficant drug resistance. We rewrite part medical treatment of rignaficant drug resistance. We rewrite part medical treatment of rignaficant drug resistance. We rewrite part medical treatment of rignaficant drug resistance. The resistance of resis	A your reply The very recommend as a second an annual case of the commend as a second an annual case of the case	102 a mind course of treatment and drug metabolism Course of treatment. I stuc metabolism Consider a metabolism Consideration of the metabolism of the meta	Taues to consider in choosing a regimen containing a regimen containing a regimen containing successful for the property of	

FIG. 18.